LOOMIS SAYLES & CO L P recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
Loomis, Sayles & Company is a private investment manager that was founded in 1926. The company focuses on delivering services to its clients through fostering performance driven investors, operating in small focused teams, making research one of its core foundations in making investment decisions, an open collegial culture, and an entrepreneurial spirit that encourages its employees to develop their own ideas in order to have “continual improvement of our performance, processes and people.” The company currently has a total of approximately $241 billion assets under management, split almost evenly between mutual funds and institutional investments. The company employs over 650 people and services institutional clients in over 20 countries in all of the major continents. Loomis, Sayles & Company has three domestic offices in Boston, Detroit, and San Francisco in the United States with its headquarters in Boston and has two international offices located in London and Singapore. The company also provides its services to pension and profit sharing plans, pooled investment vehicles, charities, high net worth individuals, and banking institutions. The company’s operating vehicles include mutual funds, hedge funds, institutional separate accounts, and collective trusts. Loomis, Sayles & Company invests in a variety of companies across the size ranges, also placing its funds in investment grade credit securities, convertibles, U.S. treasury and agencies, emerging market debts, bank and corporate loans, and securitized bonds, among others. The indices that the company use to benchmark the performance of its portfolios include the Russell indices, P 500 index, MSCI World Index, Lehman indices, and Citigroup indices. Loomis, Sayles & Company’s research utilizes a top down analysis for fixed income investments and a fundamental analysis with bottom up picking approach to manage its portfolios. Some of its mutual funds include the Core Plus Bond, Emerging Markets Opportunities, Global Bond, High Income, Global Equity and Income Fund and Value funds.
As of the latest 13F report, the guru’s equity portfolio contained 831 stocks valued at a total of $49.17Bil. The top holdings were V(4.85%), BA(4.63%), and NVDA(3.64%).
According to GuruFocus data, these were LOOMIS SAYLES & CO L P’s top five trades of the quarter.
Tesla Inc
During the quarter, LOOMIS SAYLES & CO L P bought 3,399,460 shares of NAS:TSLA for a total holding of 8,140,896. The trade had a 0.85% impact on the equity portfolio. During the quarter, the stock traded for an average price of $189.34.
On 02/12/2023, Tesla Inc traded for a price of $196.89 per share and a market cap of $622.98Bil. The stock has returned -34.66% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 5 out of 10.
In terms of valuation, Tesla Inc has a price-earnings ratio of 54.34, a price-book ratio of 13.94, a EV-to-Ebitda ratio of 34.35 and a price-sales ratio of 8.39.
The price-to-GF Value ratio is 0.49, earning the stock a GF Value rank of 4.
Deere & Co
LOOMIS SAYLES & CO L P reduced their investment in NYSE:DE by 1,071,376 shares. The trade had a 0.73% impact on the equity portfolio. During the quarter, the stock traded for an average price of $406.45.
On 02/12/2023, Deere & Co traded for a price of $417.79 per share and a market cap of $124.15Bil. The stock has returned 7.41% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Deere & Co has a price-earnings ratio of 17.91, a price-book ratio of 6.16, a price-earnings-to-growth (PEG) ratio of 0.93, a EV-to-Ebitda ratio of 15.90 and a price-sales ratio of 2.47.
The price-to-GF Value ratio is 0.96, earning the stock a GF Value rank of 6.
Meta Platforms Inc
During the quarter, LOOMIS SAYLES & CO L P bought 2,941,395 shares of NAS:META for a total holding of 14,260,620. The trade had a 0.72% impact on the equity portfolio. During the quarter, the stock traded for an average price of $117.43.
On 02/12/2023, Meta Platforms Inc traded for a price of $174.15 per share and a market cap of $451.51Bil. The stock has returned -23.71% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Meta Platforms Inc has a price-earnings ratio of 20.30, a price-book ratio of 3.62, a price-earnings-to-growth (PEG) ratio of 1.32, a EV-to-Ebitda ratio of 11.62 and a price-sales ratio of 4.03.
The price-to-GF Value ratio is 0.46, earning the stock a GF Value rank of 4.
Novartis AG
LOOMIS SAYLES & CO L P reduced their investment in NYSE:NVS by 3,983,754 shares. The trade had a 0.62% impact on the equity portfolio. During the quarter, the stock traded for an average price of $84.23.
On 02/12/2023, Novartis AG traded for a price of $86.48 per share and a market cap of $183.29Bil. The stock has returned 4.63% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Novartis AG has a price-earnings ratio of 26.58, a price-book ratio of 3.06, a price-earnings-to-growth (PEG) ratio of 4.43, a EV-to-Ebitda ratio of 11.40 and a price-sales ratio of 3.55.
The price-to-GF Value ratio is 0.93, earning the stock a GF Value rank of 6.
Regeneron Pharmaceuticals Inc
LOOMIS SAYLES & CO L P reduced their investment in NAS:REGN by 378,936 shares. The trade had a 0.54% impact on the equity portfolio. During the quarter, the stock traded for an average price of $737.86.
On 02/12/2023, Regeneron Pharmaceuticals Inc traded for a price of $757.61 per share and a market cap of $82.83Bil. The stock has returned 22.55% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 10 out of 10.
In terms of valuation, Regeneron Pharmaceuticals Inc has a price-earnings ratio of 19.81, a price-book ratio of 3.66, a price-earnings-to-growth (PEG) ratio of 0.71, a EV-to-Ebitda ratio of 14.79 and a price-sales ratio of 7.06.
The price-to-GF Value ratio is 1.13, earning the stock a GF Value rank of 3.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
